Bausch + Lomb abandons glaucoma drops after phase 2 failure
Seeking Alpha ·
Bausch + Lomb ( BLCO ) said it would end development of BL1107, an eye drop for glaucoma, after the candidate missed its primary goal in a phase 2 study. BL1107 did not lead to visual function improvements after 28 days of
DYAX Investor Sentiment
Bullish (Long) 51% · Bearish (Short) 49%
353 participants
Related News
- Air Liquide plans $200M expansion to boost production at Texas chemical site
- Micron Technology Is Quietly Setting Up for a Strong Earnings Catalyst
- Did Tesla’s Miami Robotaxi Launch and Q2 Numbers Just Shift TSLA’s Autonomy‑First Narrative?
- Amazon (AMZN) Launches Leo Broadband As Alexa Ads And AWS AI Reach Grow
- Sigma Lithium charges higher after topping Q2 production guidance
- Postmedia Network Canada Corp. GAAP EPS of -C$0.36, revenue of C$146.67M